>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

>

FDA MEDWATCH ALERTS

October 20, 2014

Lidocaine HCI Injection, USP 10 MG Per ML, 30 ML Single-Dose, Preservative-Free, by Hospira: Recall - Particulate Matter

Summary:

FDA Medwatch Alert 10-20-14

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Offers Recommendations for HHS National Action Plan for Adverse Drug Event Prevention

Friday, October 04, 2013

On October 4, ASA offered official recommendations to the U.S. Department of Health and Human Services (HHS) for further development and refinement of the Draft National Action Plan for Adverse Drug Event Prevention.  ASA’s recommendations centered on pain medicine and opioid use, development of quality measures related to adverse drug events (ADEs) and the use of the Perioperative Surgical Home to coordinate care.

The Action Plan is an effort by the federal government to seek stakeholder engagement about ADEs. The plan lists two key objectives:  to "identify common, clinically significant, preventable, and measureable" ADEs and to "align the efforts of federal health agencies to reduce patient harms from those specific ADEs nationally."

Review ASA's recommendations.
Learn more about the HHS Draft National Action Plan for Adverse Drug Event Prevention.

« Back to Washington Alerts